We are live on ! Find out more
RBFC

Roman Butler Fullerton & Co Portfolio holdings

AUM $419M
1-Year Est. Return 31.15%
This Fund
S&P 500
This Quarter Est. Return
-3.72%
1 Year Est. Return
+31.15%
3 Year Est. Return
+120.62%
5 Year Est. Return
+172.72%
10 Year Est. Return
AUM
$157M
AUM Growth
-$22.8M
Cap. Flow
-$11.8M
Cap. Flow %
-7.51%
Top 10 Hldgs %
28.08%
Holding
185
New
10
Increased
91
Reduced
50
Closed
16

Sector Composition

Rank Sector Weight
1 Technology 16.56%
2 Healthcare 15.78%
3 Financials 8.85%
4 Consumer Staples 7.56%
5 Consumer Discretionary 7.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FTNT icon
176
Fortinet
FTNT
$119B
-14,660
Closed -$883K
HRMY icon
177
Harmony Biosciences
HRMY
$2.3B
-16,494
Closed -$885K
KMB icon
178
Kimberly-Clark
KMB
$36.1B
-1,500
Closed -$202K
SEDG icon
179
SolarEdge
SEDG
$2.05B
-1,936
Closed -$515K
UTHR icon
180
United Therapeutics
UTHR
$22.1B
-6,551
Closed -$1.57M
VEU icon
181
Vanguard FTSE All-World ex-US ETF
VEU
$70B
-4,186
Closed -$204K
VGT icon
182
Vanguard Information Technology ETF
VGT
$147B
-5,264
Closed -$224K
WEC icon
183
WEC Energy
WEC
$34.8B
-2,193
Closed -$221K
XYZ
184
Block Inc
XYZ
$47.5B
-3,662
Closed -$242K
SGFY
185
DELISTED
Signify Health, Inc.
SGFY
-31,377
Closed -$519K

Similar funds

Roman Butler Fullerton & Co's Q3 2022 Portfolio in Review

As of Q3 2022, Roman Butler Fullerton & Co held 185 positions worth $157M, down 13% from $180M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Roman Butler Fullerton & Co withdrew a net $11.8M in Q3 2022, closing 16 positions and reducing 50 holdings. Its most notable exit was United Therapeutics, an estimated $1.57M position sold in full.

By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Roman Butler Fullerton & Co opened a new position in Regeneron Pharmaceuticals worth $1.35M.

  • Roman Butler Fullerton & Co's largest Q3 2022 buy was Regeneron Pharmaceuticals: 1,826 shares worth $1.35M.
  • Roman Butler Fullerton & Co added most to State Street SPDR S&P 500 ETF Trust in Q3 2022, an estimated $888K increase.
  • Roman Butler Fullerton & Co's biggest Q3 2022 reduction was NVIDIA, cutting an estimated $2.1M.
  • Roman Butler Fullerton & Co fully exited United Therapeutics in Q3 2022, selling an estimated $1.57M.
  • Roman Butler Fullerton & Co's ten largest holdings make up 28% of its $157M portfolio in Q3 2022.
  • Roman Butler Fullerton & Co opened 10 new positions and closed 16 in Q3 2022.
  • Roman Butler Fullerton & Co's portfolio value fell 13% quarter-over-quarter to $157M.

Based on Roman Butler Fullerton & Co's 13F filing for Q3 2022, filed 17 Oct 2022.